Current Report Filing (8-k)
August 28 2017 - 7:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): August 28, 2017
OPIANT PHARMACEUTICALS, INC.
(
Exact name of registrant as specified
in its charter)
|
|
|
|
|
Nevada
|
|
000-55330
|
|
46-4744124
|
(State or other jurisdiction
of
incorporation)
|
|
(Commission File Number
|
|
(IRS Employer Identification No.)
|
|
|
|
401 Wilshire Blvd., 12th Floor
Santa Monica, CA
|
|
90401
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code
|
|
(Former name or former address if changed since last report,)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
On August 28, 2017, Opiant Pharmaceuticals, Inc., a Nevada corporation
(the “Company”), issued a press release announcing the transfer of the Company's common stock, $0.001 par value per
share (the “Common Stock”), from the OTCQB Marketplace to the Nasdaq Stock Market LLC (the “Nasdaq Capital Market”).
The Company expects trading on the Nasdaq Capital Market to begin on August 29, 2017 under the trading symbol “OPNT.”
The Company's Common Stock has been trading on the OTCQB Marketplace since April 2007.
A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
Exhibit No.
|
Description
|
|
|
99.1
|
Opiant Pharmaceuticals, Inc. Press Release, dated August 28, 2017.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Opiant Pharmaceuticals, Inc.
|
|
|
|
Date: August 28, 2017
|
By:
|
/s/
Dr. Roger Crystal
|
|
|
Name: Dr. Roger Crystal
|
|
|
Title: Chief Executive Officer
|
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Apr 2023 to Apr 2024